Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
CB-03 by Shanghai Zhimeng Biopharma for Epilepsy: Likelihood of Approval
CB-03 is under clinical development by Shanghai Zhimeng Biopharma and currently in Phase I for Epilepsy. According to GlobalData, Phase...